







- ▶ **Patients 65 years of age and over** should be offered the high-dose trivalent influenza vaccine if available. If the high-dose vaccine is not available, any of the standard-dose quadrivalent vaccines should be offered.
- ▶ **Add influenza vaccination** to other visits where appropriate.
- ▶ **Patients with acute respiratory infection symptoms should defer influenza immunization** until:
 - 10 days from the onset of their symptoms or they have recovered, whichever is later; or,
 - If they test negative for COVID-19, 24 hours after their symptoms resolve or improve.

PPE required to administer influenza vaccine during the COVID-19 pandemic:	Injectable vaccines	Intranasal vaccines
	 Medical mask  Eye protection is strongly encouraged  Wear gloves only if skin on hands is not intact	 Medical mask  Eye protection is strongly encouraged  Wear gloves

Patient age	Publicly funded vaccine product	Vaccine type		Preferential vaccine
Intramuscular injectable vaccines (inactivated)				
≥ 6 months to 8 years	FluLaval Tetra (GSK), Influsplit Tetra (Fluarix®) (GSK), Fluzone® Quadrivalent (Sanofi Pasteur)	Quadrivalent-standard dose (QIV)	Egg-based	No preferential vaccine
	Children under 9 years of age who have never had a seasonal influenza vaccine need 2 doses, given 4 weeks apart.			
≥ 9 to 64 years	FluLaval Tetra (GSK), Influsplit Tetra (Fluarix®) (GSK), Fluzone® Quadrivalent (Sanofi Pasteur)	Quadrivalent-standard dose (QIV)	Egg-based	No preferential vaccine
	Flucelvax® Quad (Seqirus)**		Cell-based	
≥ 65 years and over	Fluzone® High-Dose (Sanofi Pasteur)	Trivalent-high dose (TIV)	Egg-based	Fluzone® High-Dose is preferred. If the high-dose vaccine is not available, give a standard-dose vaccine.
	FluLaval Tetra (GSK), Influsplit Tetra (Fluarix®) (GSK), Fluzone® Quadrivalent (Sanofi Pasteur) Flucelvax® Quad (Seqirus)**	Quadrivalent-standard dose (QIV)	Cell-based	
Intranasal spray vaccine (live attenuated)*				
≥ 2 to 59 years	FluMist® Quadrivalent (AstraZeneca)	Quadrivalent (Q-LAIV)	Egg-based	No preferential vaccine

Dosage for each injectable vaccination is 0.5mL; dosage for intranasal spray vaccination is 0.2mL (0.1mL in each nostril)

Contraindications (all vaccines):

- ▶ Anyone who has had a **serious allergic reaction (anaphylaxis)** to a previous dose of influenza vaccine **should not be vaccinated**. They should be referred to an allergist for further assessment.
- ▶ Anyone who has developed **Guillain-Barré Syndrome (GBS)** within six weeks of a previous influenza vaccination **should generally not be vaccinated**, however, this should be weighed against the risks of not being protected against influenza.
- ▶ Egg allergy is **NOT** a contraindication for influenza vaccination and egg-allergic individuals may be vaccinated against influenza using the full dose of any age-appropriate product.

Additional contraindications for FluMist® intranasal live attenuated vaccine include:

- ▶ Immune compromising conditions (except children with stable HIV infection on HAART (Highly Active Antiretroviral Therapy) with adequate immune function)
- ▶ Severe asthma or medically attended wheezing in the 7 days prior to vaccination
- ▶ Children 2-17 years of age currently on aspirin or aspirin-containing therapy
- ▶ Pregnant women
- ▶ Anyone who has received an anti-influenza antiviral drug in the past 48 hours

Additional Information

** New this season, Flucelvax® Quad manufactured by Seqirus is a mammalian cell culture-based inactivated influenza vaccine. It is considered effective, immunogenic, and safe in adults and children ≥ 9 years of age, and has a comparable effectiveness, immunogenicity and safety profile to traditional egg-based influenza vaccines already authorized for use in Canada. Flucelvax® Quad can be given to pregnant women. It is available at pharmacies only at the start of the season. This may change later in the season.

References & Resources

Government of Canada. Canadian Immunization Guide Chapter on Influenza and Statement on Seasonal Influenza Vaccine for 2020-2021. Ottawa, ON: October 23, 2020. Available from: <https://www.canada.ca/en/public-health/services/publications/vaccines-immunization/canadian-immunization-guide-statement-seasonal-influenza-vaccine-2020-2021.html>

Government of Canada. Interim Guidance on Continuity of Immunization Programs During the COVID-19 Pandemic. Ottawa, ON: May 13, 2020. Available from: <https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/interim-guidance-immunization-programs-during-covid-19-pandemic.html>

GSK. Influsplit Tetra (Fluarix®) Product Monograph. Radebeul, Germany: July 10, 2020. Available from: https://mcusercontent.com/52d9e9dfa66c8bca909aa4569/files/d0bd5988-a511-425c-b29e-e508f936c2a1/GSK_Influsplit_Tetra_2020_2021_PM.pdf

Ontario Ministry of Health, Drugs and Devices Division. Executive Officer Notice: Addition of Fluarix® Flu Vaccine to the Universal Influenza Immunization Program 2020/21. Toronto, ON: December 7, 2020. Available from: http://www.health.gov.on.ca/en/pro/programs/drugs/opdp_eo/notices/exec_office_20201207.pdf

Ontario Ministry of Health, Drugs and Devices Division. Executive Officer Notice: Addition of FluMist® Flu Vaccine to the Universal Influenza Immunization Program 2020/21. Toronto, ON: November 30, 2020. Available from: http://www.health.gov.on.ca/en/pro/programs/drugs/opdp_eo/notices/exec_office_20201130.pdf

Ontario Ministry of Health. Guidance for Immunization Service Providers During COVID-19. Toronto, ON. Available from: <https://www.toronto.ca/wp-content/uploads/2020/04/94f3-Immunization-Guidance-April-19-2020-E2.pdf>

Ontario Ministry of Health. Health Care Provider Qs & As: FluMist® Quadrivalent. Toronto, ON: November 26, 2020. Available from: http://www.health.gov.on.ca/en/pro/programs/publichealth/flu/uiip/docs/2020-21_UIIP_FluMist-HCP_Fact_Sheet.pdf

Ontario Ministry of Health. Health Care Provider Qs & As: Information for the 2020/2021 Influenza Season. Toronto, ON: September 21, 2020. Available from: http://health.gov.on.ca/en/pro/programs/publichealth/flu/uiip/docs/flu_uiip_HCP_QA_2020-21.pdf

Ontario Ministry of Health. Health Care Provider Qs & As: Information for Individuals 6 months to 64 years of age. Toronto, ON: September 21, 2020. Available from: http://health.gov.on.ca/en/pro/programs/publichealth/flu/uiip/docs/flu_uiip_6mo-64yrs_2020-21.pdf

Ontario Ministry of Health. Health Care Provider Qs & As: Information for Individuals ≥65 years of age. Toronto, ON: September 21, 2020. Available from: http://health.gov.on.ca/en/pro/programs/publichealth/flu/uiip/docs/flu_uiip_65yrs_older_2020-21.pdf

Public Health Ontario. Influenza Vaccines for the 2020-2021 Influenza Season. Toronto, ON: September 21, 2020. Available from: <https://www.publichealthontario.ca/-/media/documents/f/2020/fact-sheet-influenza-vaccine-2020-2021.pdf?la=en>